SECOVID: A Multi-center, Randomized, Dose-ranging Parallel-group Trial Assessing the Efficacy of Sirolimus in Hospitalized Patients With COVID-19 Pneumonia for the Prevention of Post-COVID Fibrosis
Latest Information Update: 23 Nov 2022
At a glance
- Drugs Sirolimus (Primary)
- Indications Pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms SECOVID
- 18 Nov 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2024.
- 18 Nov 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2024.
- 09 Jul 2021 Status changed from not yet recruiting to recruiting.